Hunting drug targets by systems-level modeling of gene expression profiles.
Structural learning of Bayesian networks applied to sets of genome-wide expression patterns has been recently discovered as a potentially useful tool for the systems-level statistical description of gene interactions. We train and analyze Bayesian networks with the goal of inferring biological aspects of gene function. Our two-component approach focuses on supporting the drug discovery process by identifying genes with central roles for the network operation, which could act as drug targets. The first component, referred to as scale-free analysis, uses topological measures of the network-related to a high-traffic load of genes-as estimators for their functional importance. The second component, referred to as generative inverse modeling, is a method of estimating the effect of a simulated drug treatment or mutation on the global state of the network, as measured in the expression profile. We show for a dataset from acute lymphoblastic leukemia patients that both approaches are suitable for finding genes with central cellular functions. In addition, generative inverse modeling correctly identifies a known oncogene in a purely data-driven way.
Corporate Technology, Information and Communications, Siemens AG, Munich D-81730, Germany.
Mathaeus
M
Dejori
Bernd
B
Schuermann
Martin
M
Stetter
D000465:Algorithms; D000818:Animals; D001499:Bayes Theorem; D014408:Biomarkers, Tumor / Q000378:metabolism*; D003198:Computer Simulation; D016503:Drug Delivery Systems / Q000379:methods*; D015195:Drug Design; D020869:Gene Expression Profiling / Q000379:methods*; D005786:Gene Expression Regulation; D006801:Humans; D008954:Models, Biological; D015233:Models, Statistical; D020411:Oligonucleotide Array Sequence Analysis / Q000379:methods; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000378:metabolism*; D020543:Proteome / Q000378:metabolism; D015398:Signal Transduction
D014408:Biomarkers, Tumor; D020543:Proteome